Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeligekimab in Uncontrolled Seasonal Allergic Rhinitis
NCT06028490Phase 2Unknown
- Sponsor
- Zheng Liu ENT
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of xeligekimab in allergic rhinitis (AR), sponsored by Zheng Liu ENT. Status: unknown.
02
Drugs
xeligekimab
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06028490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028490.